Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with PharmaCell B.V and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL; and the University of Texas M.D. Anderson Cancer Center for multi-arm clinical trials for TIL therapy. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IOVA
Previous Symbol
CUSIPN/A
Phone650-260-7120
Debt
Debt-to-Equity RatioN/A
Current Ratio15.95
Quick Ratio15.95
Price-To-Earnings
Trailing P/E Ratio-6.77
Forward P/E Ratio-7.69
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.66 per share
Price / Book3.59
Profitability
EPS (Most Recent Fiscal Year)($1.41)
Net Income$-92,060,000.00
Net MarginsN/A
Return on Equity-48.55%
Return on Assets-45.91%
Miscellaneous
Employees63
Outstanding Shares95,590,000
Market Cap$896.66 million
OptionableOptionable
Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions
What is Iovance Biotherapeutics' stock symbol?
Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."
How were Iovance Biotherapeutics' earnings last quarter?
Iovance Biotherapeutics Inc (NASDAQ:IOVA) posted its earnings results on Tuesday, November, 6th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by $0.03. View Iovance Biotherapeutics' Earnings History.
When is Iovance Biotherapeutics' next earnings date?
What price target have analysts set for IOVA?
8 brokers have issued 12-month price objectives for Iovance Biotherapeutics' shares. Their predictions range from $19.00 to $31.00. On average, they anticipate Iovance Biotherapeutics' stock price to reach $25.4286 in the next year. This suggests a possible upside of 166.5% from the stock's current price. View Analyst Price Targets for Iovance Biotherapeutics.
What is the consensus analysts' recommendation for Iovance Biotherapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iovance Biotherapeutics.
What are Wall Street analysts saying about Iovance Biotherapeutics stock?
Here are some recent quotes from research analysts about Iovance Biotherapeutics stock:
- 1. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We reiterate our Buy rating and price target of $26. Our target is based on our clinical net present value (NPV) model, which derives its primary value from LN-144 for metastatic melanoma currently. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (11/12/2018)
- 2. According to Zacks Investment Research, "Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. " (10/17/2018)
- 3. Chardan Capital analysts commented, "We now affirm our conviction view, seeing renewed opportunities for vast share price upside after a recent stock pullback. (On page 2 of this research, we highlight the vast opportunity in refractory melanoma.) Iovance’s recent pullback in stock performance may be due to a misunderstanding from erroneous reports regarding rights to TILs, and therefore presents a buying opportunity ahead of data readouts. We note the pullback coincided with the recent publication in a case study from Steven Rosenberg’s group at the National Cancer Institute (NCI) demonstrating remarkable efficacy of autologous TIL therapy in a patient with chemorefractory breast cancer. However, it was erroneously reported in multiple news outlets that Gilead (unrated) subsidiary Kite had signed an agreement for rights to the technology." (7/6/2018)
Has Iovance Biotherapeutics been receiving favorable news coverage?
Media coverage about IOVA stock has been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Iovance Biotherapeutics earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future.
Who are some of Iovance Biotherapeutics' key competitors?
Some companies that are related to Iovance Biotherapeutics include Allogene Therapeutics (ALLO), argenx (ARGX), Repligen (RGEN), Acceleron Pharma (XLRN), China Biologic Products (CBPO), Regenxbio (RGNX), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Spark Therapeutics (ONCE), Atara Biotherapeutics (ATRA), Autolus Therapeutics (AUTL), Editas Medicine (EDIT) and Orchard Therapeutics (ORTX).
Who are Iovance Biotherapeutics' key executives?
Iovance Biotherapeutics' management team includes the folowing people:
- Dr. Maria Fardis, CEO, Pres & Director (Age 50)
- Mr. Timothy E. Morris, CFO, Principal Accounting Officer & Corp. Sec. (Age 56)
- Dr. Frederick G. Vogt Ph.D., Esq., Gen. Counsel (Age 44)
- Mr. Howard B. Johnson, Sr. VP of Corp. Devel., Alliance Management & Program Management (Age 58)
- Dr. Elma S. Hawkins Ph.D., MBA, Advisor to the Board (Age 61)
Who are Iovance Biotherapeutics' major shareholders?
Iovance Biotherapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (7.63%), BlackRock Inc. (6.96%), Franklin Resources Inc. (5.42%), Victory Capital Management Inc. (2.54%), Acuta Capital Partners LLC (2.33%) and Credit Suisse AG (1.63%). View Institutional Ownership Trends for Iovance Biotherapeutics.
Which institutional investors are selling Iovance Biotherapeutics stock?
IOVA stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, FMR LLC, Franklin Resources Inc., Virtus ETF Advisers LLC, Vident Investment Advisory LLC, JPMorgan Chase & Co. and JPMorgan Chase & Co.. View Insider Buying and Selling for Iovance Biotherapeutics.
Which institutional investors are buying Iovance Biotherapeutics stock?
IOVA stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, FIL Ltd, Credit Suisse AG, Osterweis Capital Management Inc., Cheyne Capital Management UK LLP, Stanley Laman Group Ltd., BlackRock Inc. and Opaleye Management Inc.. View Insider Buying and Selling for Iovance Biotherapeutics.
How do I buy shares of Iovance Biotherapeutics?
Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Iovance Biotherapeutics' stock price today?
One share of IOVA stock can currently be purchased for approximately $9.54.
How big of a company is Iovance Biotherapeutics?
Iovance Biotherapeutics has a market capitalization of $896.66 million. The biotechnology company earns $-92,060,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. Iovance Biotherapeutics employs 63 workers across the globe.
What is Iovance Biotherapeutics' official website?
How can I contact Iovance Biotherapeutics?
Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]
MarketBeat Community Rating for Iovance Biotherapeutics (NASDAQ IOVA)
MarketBeat's community ratings are surveys of what our community members think about Iovance Biotherapeutics and other stocks. Vote "Outperform" if you believe IOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
